Wegovy's benefits beyond weight loss: what the evidence actually shows

The misconception worth correcting first

There is a widespread assumption that Wegovy is a weight-loss drug and only a weight-loss drug — that any other benefit is a pleasant side effect of dropping a few kilograms. That framing is too simple, and it does the science a disservice. Regulatory agencies do not approve medicines for cardiovascular risk reduction on the strength of a knock-on effect. They require independent evidence that the medicine itself is doing something meaningful. In the case of semaglutide, that evidence now exists and has been formally recognised.

This matters practically. Someone using Wegovy for weight management may be receiving cardiovascular protection at the same time, not as a bonus but as a pharmacologically distinct effect, one that operates through the GLP-1 receptor pathway on the heart and vasculature, not solely through calories lost. Understanding this changes how clinicians and patients think about the value of the treatment.

For a thorough grounding in what semaglutide is and how it works, the semaglutide overview on this site covers the mechanism in plain terms.

Cardiovascular risk: the approved UK indication

The most significant non-weight benefit with the clearest regulatory footing is cardiovascular protection. Wegovy holds a UK licence for reducing the risk of major adverse cardiovascular events (including heart attack, stroke and cardiovascular death) in adults with established cardiovascular disease and a BMI of 30 or above. This indication is separate from, and sits alongside, the weight management licence.

The SELECT trial, a large randomised controlled study of adults with pre-existing cardiovascular disease and obesity (but without diabetes), found that semaglutide 2.4mg reduced the composite rate of major cardiovascular events by around 20% compared with placebo over a median follow-up of just over three years. Crucially, the benefit appeared early and was not explained entirely by weight reduction, participants who lost less weight still saw meaningful cardiovascular benefit. The NHS's own patient-level information on semaglutide references this indication alongside weight management.

For people with heart disease who are also managing their weight, this makes the medicine's risk-benefit calculation meaningfully different from a product that only shifts numbers on the scale. Our detailed page on Wegovy's benefits beyond weight loss maps this evidence in full.

Liver disease: the newest approved indication

On 3 July 2026, the MHRA granted conditional approval for semaglutide (Wegovy) as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis. This makes Wegovy, at the time of writing, the first GLP-1 medicine to receive a liver-disease indication in the UK.

MASH is a serious progressive form of fatty liver disease linked to metabolic conditions including obesity and type 2 diabetes. Standard management has historically been limited to lifestyle change and treating the underlying metabolic risk factors. The conditional approval, confirmed by the MHRA's announcement on GOV.UK in July 2026, reflects evidence that semaglutide can reduce liver inflammation and fibrosis beyond what weight reduction alone would predict.

It is worth being clear: at present, nume prescribes Wegovy for weight management. The liver-disease indication sits within a specialist clinical pathway. But if you have been told you have fatty liver disease and are also exploring what Wegovy is used for, this approval is highly relevant context for a conversation with your GP or specialist.

Metabolic markers and what the trials also show

Beyond the formally approved indications, the clinical trial programme for semaglutide has consistently recorded improvements in a range of metabolic measures alongside weight reduction: lower systolic blood pressure, improved LDL and triglyceride profiles, reductions in HbA1c in people with prediabetes or type 2 diabetes, and lower levels of C-reactive protein, a marker of systemic inflammation. These are not currently the basis of separate licensed indications in the UK for the weight-management formulation, so it would be inaccurate to describe them as approved benefits. They are, however, consistent findings that inform how clinicians weigh the treatment's overall value.

The SELECT trial's cardiovascular data were notable partly because they prompted researchers to think differently about GLP-1 receptor agonists as a class: the benefit appears to go beyond the metabolic effects of weight loss and into direct anti-inflammatory and vascular effects. The research community is now investigating semaglutide in kidney disease, addiction, and several other areas. Some of those trials are still running.

If you are weighing up the broader clinical picture before deciding whether this treatment fits your situation, our overview of semaglutide's benefits pulls together the current evidence clearly, and you can read more about the specific semaglutide benefits for weight loss if that is the primary reason you are considering treatment. And if cost is part of the calculation, the Wegovy price comparison page gives honest context on what UK private treatment typically involves. When you are ready to find out whether you are eligible, check your eligibility with our prescribers.